Advertisement
Screener

PACIRA BIOSCIENCES, INC. (PCRX) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

PACIRA BIOSCIENCES, INC. Increase (Decrease) in Deferred Revenue

PACIRA BIOSCIENCES, INC. (PCRX) reported Increase (Decrease) in Deferred Revenue of $125.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2022-02-28

  • PACIRA BIOSCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was -$205.00K.
  • PACIRA BIOSCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2016-12-31 was -$357.00K.
  • PACIRA BIOSCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2016-09-30 was -$356.00K.
  • PACIRA BIOSCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2016-06-30 was -$357.00K.
  • PACIRA BIOSCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2021 was $125.00K.
  • PACIRA BIOSCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2020 was $0.00.
  • PACIRA BIOSCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2019 was $0.00.
  • PACIRA BIOSCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2016 was -$1.43M.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2021-12-31$125.00K
10-K · filed 2022-02-28
2020-12-31$0.00
10-K · filed 2022-02-28
2019-12-31$0.00
10-K · filed 2022-02-28
2017-03-31-$205.00K
10-Q · filed 2017-05-04
-$562.00K
derived: sum of 2 quarters · filed 2017-05-04
-$918.00K
derived: sum of 3 quarters · filed 2017-05-04
-$1.27M
derived: sum of 4 quarters · filed 2017-05-04
2016-12-31-$357.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
-$713.00K
derived: sum of 2 quarters · filed 2017-03-01
-$1.07M
derived: sum of 3 quarters · filed 2017-03-01
-$1.43M
10-K · filed 2017-03-01
2016-09-30-$356.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02
-$713.00K
derived: sum of 2 quarters · filed 2016-11-02
-$1.07M
10-Q · filed 2016-11-02
-$1.43M
derived: sum of 4 quarters · filed 2017-05-04
2016-06-30-$357.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
-$713.00K
10-Q · filed 2016-08-04
-$1.07M
derived: sum of 3 quarters · filed 2017-05-04
-$1.43M
derived: sum of 4 quarters · filed 2017-05-04
2016-03-31-$356.00K
10-Q · filed 2017-05-04
-$713.00K
derived: sum of 2 quarters · filed 2017-05-04
-$1.07M
derived: sum of 3 quarters · filed 2017-05-04
-$1.43M
derived: sum of 4 quarters · filed 2017-05-04
2015-12-31-$357.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
-$713.00K
derived: sum of 2 quarters · filed 2017-03-01
-$1.07M
derived: sum of 3 quarters · filed 2017-03-01
-$1.43M
10-K · filed 2017-03-01
2015-09-30-$356.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02
-$713.00K
derived: sum of 2 quarters · filed 2016-11-02
-$1.07M
10-Q · filed 2016-11-02
$5.64M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30-$357.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
-$713.00K
10-Q · filed 2016-08-04
$6.00M
derived: sum of 3 quarters · filed 2017-03-01
$5.64M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31-$356.00K
10-Q · filed 2016-05-02
$6.36M
derived: sum of 2 quarters · filed 2017-03-01
$6.00M
derived: sum of 3 quarters · filed 2017-03-01
$13.68M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$6.71M
10-K · filed 2017-03-01
$6.36M
derived: sum of 2 quarters · filed 2017-03-01
$14.04M
derived: sum of 3 quarters · filed 2017-03-01
$6.71M
10-K · filed 2016-02-25
2014-09-30-$356.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27
$7.32M
derived: sum of 2 quarters · filed 2015-10-27
$7.07M
10-Q · filed 2015-10-27
$7.33M
derived: sum of 4 quarters · filed 2016-02-25
2014-06-30$7.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30
$7.43M
10-Q · filed 2015-07-30
$7.68M
derived: sum of 3 quarters · filed 2016-02-25
$7.44M
derived: sum of 4 quarters · filed 2016-02-25
2014-03-31-$252.00K
10-Q · filed 2015-04-30
$5.00K
derived: sum of 2 quarters · filed 2016-02-25
-$238.00K
derived: sum of 3 quarters · filed 2016-02-25
-$481.00K
derived: sum of 4 quarters · filed 2016-02-25
2013-12-31$257.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
$14.00K
derived: sum of 2 quarters · filed 2016-02-25
-$229.00K
derived: sum of 3 quarters · filed 2016-02-25
-$472.00K
10-K · filed 2016-02-25
2013-09-30-$243.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30
-$486.00K
derived: sum of 2 quarters · filed 2014-10-30
-$729.00K
10-Q · filed 2014-10-30
-$1.55M
derived: sum of 4 quarters · filed 2015-02-24
2013-06-30-$243.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31
-$486.00K
10-Q · filed 2014-07-31
-$1.30M
derived: sum of 3 quarters · filed 2015-02-24
-$4.78M
derived: sum of 4 quarters · filed 2015-02-24
2013-03-31-$243.00K
10-Q · filed 2014-05-01
-$1.06M
derived: sum of 2 quarters · filed 2015-02-24
-$4.54M
derived: sum of 3 quarters · filed 2015-02-24
-$10.86M
derived: sum of 4 quarters · filed 2015-02-24
2012-12-31-$817.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
-$4.29M
derived: sum of 2 quarters · filed 2015-02-24
-$10.61M
derived: sum of 3 quarters · filed 2015-02-24
-$16.78M
10-K · filed 2015-02-24
2012-09-30-$3.48M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31
-$9.79M
derived: sum of 2 quarters · filed 2013-10-31
-$15.96M
10-Q · filed 2013-10-31
-$14.69M
derived: sum of 4 quarters · filed 2014-02-25
2012-06-30-$6.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
-$12.48M
10-Q · filed 2013-08-06
-$11.21M
derived: sum of 3 quarters · filed 2014-02-25
-$11.88M
derived: sum of 4 quarters · filed 2014-02-25
2012-03-31-$6.17M
10-Q · filed 2013-05-08
-$4.90M
derived: sum of 2 quarters · filed 2014-02-25
-$5.57M
derived: sum of 3 quarters · filed 2014-02-25
-$6.10M
derived: sum of 4 quarters · filed 2014-02-25
2011-12-31$1.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25
$598.00K
derived: sum of 2 quarters · filed 2014-02-25
$65.00K
derived: sum of 3 quarters · filed 2014-02-25
$1.06M
10-K · filed 2014-02-25
2011-09-30-$671.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01
-$1.20M
derived: sum of 2 quarters · filed 2012-11-01
-$204.00K
10-Q · filed 2012-11-01
-$744.00K
derived: sum of 4 quarters · filed 2013-03-07
2011-06-30-$533.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
$467.00K
10-Q · filed 2012-08-09
-$73.00K
derived: sum of 3 quarters · filed 2013-03-07
-$649.00K
derived: sum of 4 quarters · filed 2013-03-07
2011-03-31$1.00M
10-Q · filed 2012-05-09
$460.00K
derived: sum of 2 quarters · filed 2013-03-07
-$116.00K
derived: sum of 3 quarters · filed 2013-03-07
2010-12-31-$540.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-07
-$1.12M
derived: sum of 2 quarters · filed 2013-03-07
-$2.33M
10-K · filed 2013-03-07
2010-09-30-$576.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31
-$1.79M
10-Q · filed 2011-10-31
2010-06-30-$1.21M
10-Q · filed 2011-08-11
2009-12-31$3.79M
10-K · filed 2012-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Savara Inc (SVRA)United States$1.044B-9.10
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93